Patents by Inventor Baranyai Zsolt

Baranyai Zsolt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of L-Histidine and derivatives thereof
    Patent number: 9012483
    Abstract: The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered as a single oral dose comprised from 0.2-20 g.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: April 21, 2015
    Assignee: Bracco Imaging S.p.A.
    Inventors: Baranyai Zsolt, Ernö Brücher, Simona Bussi, Alessandro Maiocchi, Fulvio Uggeri
  • NEW USE OF L-HISTIDINE AND DERIVATIVES THEREOF
    Publication number: 20140155449
    Abstract: The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered a s a single oral dose comprised from 0.2-20 g.
    Type: Application
    Filed: July 24, 2012
    Publication date: June 5, 2014
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Baranyai Zsolt, Ernö Brücher, Simona Bussi, Alessandro Maiocchi, Fulvio Uggeri